High-density lipoprotein mimetics: focus on synthetic high-density lipoprotein.
Epidemiologic studies show an inverse relation between high-density lipoprotein (HDL) cholesterol levels and coronary artery disease, and proof-of-concept experimental studies suggest that HDL and its apolipoproteins, specifically apolipoprotein (apo) A-I , have atheroprotective effects. Atheroprotective effects of HDL are attributed to its ability to remove macrophage cholesterol by stimulating reverse cholesterol transport as well as anti-inflammatory and antioxidant effects. Several different strategies are currently being pursued to exploit the vascular-protective effects of HDL. One such approach involves direct administration of synthetic reconstituted HDL made from linking phospholipid carriers with recombinant mutant apoA-I or plasma-derived wild-type apoA-I.
Shah
Prediman K
PK
Division of Cardiology & Atherosclerosis Research Center, Cedars Sinai Medical Center, Los Angeles, California 90048, USA. shahp@cschs.org
D016632:Apolipoprotein A-I / Q000008:administration & dosage / Q000096:biosynthesis*; D008076:Cholesterol, HDL / Q000502:physiology*; D003324:Coronary Artery Disease / Q000188:drug therapy* / Q000517:prevention & control; D006801:Humans; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000096:biosynthesis*
D016632:Apolipoprotein A-I; D008076:Cholesterol, HDL; D011994:Recombinant Proteins